Allison E. Norlander, PhD
Assistant Professor of Anatomy, Cell Biology & Physiology
- Phone
- (317) 274-7410
- Address
-
MS 387
ANAT
IN
Indianapolis, IN - PubMed:
-
Bio
Allison E. Norlander, PhD, is an Assistant Professor in the Department of Anatomy, Cell Biology, and Physiology with a joint appointment in the Krannert Cardiovascular Research Center at Indiana University School of Medicine. Dr. Norlander received her bachelor’s degree from the University of Pittsburgh and subsequently completed her PhD at Vanderbilt University. Dr. Norlander completed her postdoctoral fellowship at Vanderbilt University Medical Center. Dr. Norlander’s work focuses on the study of T cells in inflammation. She has several projects focusing on understanding the impact of PGI2 on T cells in Allergic Airway Inflammation and Hypertension.
Read more about the Norlander Lab!
Key Publications
Norlander AE, Bloodworth MH, Toki S, Zhang J, Zhou W, Boyd KL, Polosukhin VV, Cephus JY, Ceneviva ZJ, Gandhi VD, Chowdhury NU, Charbonnier LM, Rogers LM, Wang J, Aronoff DM, Bastarache L, Newcomb DC, Chatila TA, Peebles RS Jr. Prostaglandin I2 signaling licenses Treg suppressive function and prevents pathogenic reprogramming. The Journal of Clinical Investigation. 2021 February 2. PMID: 33529171
Norlander AE, Saleh MA, Itani HA, Pandey AK, Wu J, Xiao L, Dale BL, Harrison DG, Madhur MS. T cell Specific Deletion of Serum and Glucocorticoid-Regulated Kinase 1 Attenuates Hypertension and End-Organ Inflammation. JCI Insight. 2017 July 6. PMID: 28679951.
Norlander AE, Saleh MA, Kamat N, Ko B, Gnecco J, Zhu L, Dale B, Iwakura Y, Hoover R, McDonough A, Madhur MS. Interleukin 17A Regulates Renal Sodium Transporters and Renal Injury in Angiotensin II- Induced Hypertension. Hypertension. 2016 May 2. PMID: 27141060.
| Year | Degree | Institution |
|---|---|---|
| 2017 | PhD | Vanderbilt University |
| 2012 | BS | University of Pittsburgh |
See more here!!! Norlander Lab
Hypertension, defined as blood pressure ≥ 130/80 mmHg, has become a worldwide health concern, and affects 46% of adults in the United States. Recent studies have linked the immune system to the development and pathogenesis of hypertension. Generation of tolerance to self and the promotion of anti-inflammatory pathways are potential avenues for the development of drugs to treat of hypertension.
In the last 50 years, allergic diseases such as allergic rhinitis (runny nose), asthma, food allergy, and atopic eczema (skin allergy) have been spreading rapidly. Allergen tolerance can be considered as a non-pathogenic immune response to allergen. Discovery of factors that promote tolerance to an allergy or that promote an anti-inflammatory response, are critical to reverse the increasing number and severity of allergic diseases.
Therefore, better understanding the inflammatory and immune-mediated mechanisms promoting disease pathogenesis could result in the development of drugs to treat allergy, asthma, and/or hypertension.
The Norlander Lab evaluates human cells from patients with disease and utilizes mouse models that recapitulate disease to better understand cell-type functionality, pathway alterations, and treatments of interest. Specifically, the lab is currently interested in understanding how PGI2 or Prostaglandin I2 is augmenting T regulatory cell and T follicular helper cell function in hypertension and allergy/asthma.